

## Accepted Manuscript

SREBP-1a activation by HBx and the effect on hepatitis B virus enhancer II/  
core promoter

Ling Qiao, Qi Wu, Xinya Lu, Yan Zhou, Ana Fernández-Alvarez, Lihong Ye,  
Xiaodong Zhang, Jihong Han, Marta Casado, Qiang Liu


PII: S0006-291X(13)00277-5  
DOI: <http://dx.doi.org/10.1016/j.bbrc.2013.02.030>  
Reference: YBBRC 29976

To appear in: *Biochemical and Biophysical Research Communi-  
cations*

Received Date: 24 January 2013

Please cite this article as: L. Qiao, Q. Wu, X. Lu, Y. Zhou, A. Fernández-Alvarez, L. Ye, X. Zhang, J. Han, M. Casado, Q. Liu, SREBP-1a activation by HBx and the effect on hepatitis B virus enhancer II/core promoter, *Biochemical and Biophysical Research Communications* (2013), doi: <http://dx.doi.org/10.1016/j.bbrc.2013.02.030>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **SREBP-1a activation by HBx and the effect on hepatitis B virus enhancer II/core promoter**

2 Ling Qiao<sup>a,1,2</sup>, Qi Wu<sup>a,2</sup>, Xinya Lu<sup>a</sup>, Yan Zhou<sup>a</sup>, Ana Fernández-Alvarez<sup>b</sup>, Lihong Ye<sup>c</sup>, Xiaodong  
3 Zhang<sup>c</sup>, Jihong Han<sup>c</sup>, Marta Casado<sup>b</sup>, and Qiang Liu<sup>a,\*</sup>

4 <sup>a</sup>Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK,  
5 Canada S7N 5E3

6 <sup>b</sup>Instituto de Biomedicina de Valencia, Spanish Council for Scientific Research (CSIC), Valencia,  
7 Spain

8 <sup>c</sup>College of Life Sciences, Nankai University, Tianjin, China

9

10 Running title: HBx activates HBV enhancer II/core promoter through SREBP-1

11

12 \*Corresponding author

13 Qiang Liu, Ph.D.

14 Vaccine and Infectious Disease Organization

15 University of Saskatchewan

16 120 Veterinary Road

17 Saskatoon, SK

18 Canada S7N 5E3

19 Phone: 1-306-966 1567

20 Fax: 1-306-966 7478

21 E-mail: [qiang.liu@usask.ca](mailto:qiang.liu@usask.ca)

22

23 Word counts:

24 Abstract: 210

<sup>1</sup>Present address: 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormones and Development (Ministry of Health), Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China

<sup>2</sup>These authors contributed equally to this study.

25 Text: 4597

26 Figures: 4

27

28 **Abstract**

29 Hepatitis B virus (HBV) X protein (HBx) plays an important role in HBV pathogenesis by  
30 regulating gene expression. Sterol regulatory element binding protein-1a (SREBP-1a) is a key  
31 transcriptional factor for modulating fatty acid and cholesterol synthesis. Here we demonstrated that HBx  
32 increased mature SREBP-1a protein level in the nucleus and its activity as a transcription factor. We  
33 further showed that the up-regulation of SREBP-1a by HBx occurred at the transcriptional level after  
34 ectopic expression and in the context of HBV replication. Deletional analysis using SREBP-1a promoter  
35 revealed that the sequence from -436 to -398 in the promoter was required for its activation by HBx. This  
36 promoter region possesses the binding sequences for two basic leucine zipper (b-ZIP) transcription  
37 factors, namely C/EBP and E4BP4. Mutagenesis of the binding sequences on the SREBP-1a promoter and  
38 ectopic expression experiments demonstrated that C/EBP $\alpha$  enhanced SREBP-1a activation by HBx, while  
39 E4BP4 had an inhibitory effect. C/EBP $\alpha$  was able to significantly reverse the inhibitory activity of E4BP4  
40 on SREBP-1a promoter. These results demonstrated that HBx activates SREBP-1a activity at the  
41 transcription level through a complex mechanism involving two bZIP transcription factors C/EBP and  
42 E4BP4 with C/EBP being the dominant positive factor. Finally, we showed that knocking down SREBP-1  
43 abolishes HBV enhancer II/core promoter activation by HBx.

44

45 **Keywords:** HBx; SREBP-1a; C/EBP; E4BP4; HBV enhancer II/core promoter; transcription

46

[Type text]

## 47 **1. Introduction**

48 Sterol regulatory element-binding proteins (SREBPs) belong to the family of basic-helix-loop-helix-  
49 leucine zipper (bHLH-ZIP) transcription factors [11]. SREBPs directly activate the expression of  
50 numerous genes linked to the synthesis and uptake of cholesterol, fatty acids, triglycerides, and  
51 phospholipids. The mammalian genome encodes three SREBPs, designated SREBP-1a, SREBP-1c, and  
52 SREBP-2 [33]. In comparison to SREBP-1c, SREBP-1a has a longer transcription activation domain at its  
53 N-terminus which is capable of recruiting co-activators for transcription [33]. As such, SREBP-1a is a  
54 more potent activator of all SREBP-responsive genes for fatty acid and cholesterol synthesis, whereas  
55 SREBP-1c can only activate fatty acid synthesis [12;29]. SREBPs are synthesized as inactive precursors  
56 and the N-terminal portion, released from the SREBP precursor by proteolysis, enters the nucleus and  
57 becomes active transcriptional factors [3]. Nuclear SREBPs activate transcription by binding to SRE  
58 sequence in the promoter regions of target genes [11].

59 Hepatitis B virus (HBV) infection is a global health problem with 350 to 400 million people being  
60 chronic carriers [2]. HBV has a partially double-stranded circular DNA genome coding for core, surface,  
61 polymerase, and the X (HBx) proteins [6]. Two viral enhancers promote HBV transcription [23].  
62 Enhancer II/core promoter sequence regulates the transcription of 3.5-kb pregenomic RNA, a key step in  
63 HBV replication cycle. HBx increases HBV replication and activates HBV enhancer II/core promoter  
64 [5;15;21]. HBx also modulates host cellular functions including lipid metabolism [25;32]. In this study,  
65 we investigated activation of SREBP-1a by HBx and its involvement in regulating HBV enhancer II/core  
66 promoter by HBx.

## 67 **2. Materials and Methods**

### 68 *2.1. Plasmids and antibodies*

69 The coding sequence of HBx was amplified by PCR from plasmids pRBK HBx or pawy1.2 [8;28] and  
70 cloned in-frame with the myc tag into the pEF/cyto/myc vector (Invitrogen). HBV enhancer II/core  
71 promoter sequence [27] was cloned into pGL4.14 vector (Promega), generating pGL4-HBV EN2/CP  
72 [Type text]

73 where the expression of luciferase gene was controlled by HBV enhancer II/core promoter. Flag-tagged  
74 SREBP-1a (aa. 1-517) was amplified from an SREBP-1a plasmid [30] and inserted into the pCMV2 Flag  
75 vector (Sigma-Aldrich) [14]. Plasmid pSRE-Luc containing three copies of SRE sequences was provided  
76 by Dr. Shimano [1]. Human SREBP-1a promoter - luciferase reporters containing different lengths of the  
77 SREBP-1a promoter were described previously [10]. Mutant SREBP-1a promoters with mutations for the  
78 binding sequences for C/EBP (CCAAT/enhancer binding protein) and E4BP4 (Adenovirus E4 promoter  
79 binding protein 4) were generated by site-directed mutagenesis and confirmed by DNA sequencing  
80 (Figure 3). Plasmids expressing C/EBP $\alpha$  [4] and E4BP4 (Open Biosystems) were used. SREBP-1-  
81 targeting microRNA (miRNA) with target sequence of 5' CCTGGTCTACCATAAGCTGCA 3' was  
82 constructed in pcDNA6.2-GW/EmGFP miR vector (Invitrogen).

83 SREBP-1, Flag (M2), fibrillarin,  $\beta$ -actin and Myc epitope antibodies were from Santa Cruz  
84 Biotechnology, Sigma-Aldrich, and Cell Signaling Technology, respectively. Anti-HBx antibody was  
85 provided by Dr. Richardson [8].

86

### 87 *2.2. Cell culture, transfection and nuclear fractionation*

88 Huh-7 cells [20] were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% (v/v)  
89 fetal bovine serum (FBS). Huh-7 cells were transfected using the calcium phosphate precipitation method  
90 as previously described [13]. Nuclear fractions were isolated as described [36].

91

### 92 *2.3. Immunoblotting analysis*

93 Huh-7 cells were collected with a Cell Lysis Buffer (Cell Signaling Technology) containing 1 mM  
94 phenylmethylsulphonyl fluoride (PMSF). Immunoblotting was performed as described [14;36]. For  
95 SREBP experiments, cells were treated with a protease inhibitor ALLN (25  $\mu$ g/ml, Calbiochem) for 1  
96 hour prior to lysis.

97

[Type text]

98        *2.4. Reverse transcription and real-time PCR*

99        RNA was isolated from Huh-7 cells with Trizol (Invitrogen) followed by DNase I (Invitrogen)  
100 digestion. Reverse transcription was carried out by Superscript II (Invitrogen) and random priming. Real-  
101 time PCR was performed with primers SREBP-1a-FD (5' CGCTGCTGACCGACAT 3') and SREBP-1a-  
102 rev (5' CAAGAGAGGAGCTCAATG 3') using SYBR Green based detection system. Housekeeping  
103 gene GUSB was amplified in parallel by primers GUSB-FD (5' GGTGCTGAGGATTGGCAGTG 3') and  
104 GUSB-rev (5' CGCACTTCCAACCTTGAACAGG 3'). Data was analyzed by Bio-Rad iQ5 program.

105

106        *2.5. Luciferase assay*

107        Huh-7 cells were lysed in a Passive Lysis Buffer (Promega) and luciferase activity was determined  
108 using luciferase assay reagents (Promega) in a TD 20/20 Luminometer (Turner Designs). Results were  
109 analyzed for statistical differences using Student *t* test. A *p* value of  $\leq 0.05$  was considered statistically  
110 significant.

111

112        **3. Results**

113        *3.1. HBx increases the level of SREBP-1a in the nucleus*

114        HBx coding sequence was cloned into the pEF-cyto-myc vector in-frame with the myc tag. The  
115 resulting plasmid was transfected into Huh-7 cells and the cell lysates were analyzed in immunoblotting.  
116 As shown in Fig. 1A, a specific protein band was recognized by an HBx-specific antibody and a myc-tag  
117 antibody (not shown) in cells transfected with HBx-expressing plasmid, but not in vector-transfected cells.  
118 The level of  $\beta$ -actin was used as loading control. These results demonstrated the expression of HBx  
119 protein after transfection.

120        Given the importance of SREBP-1a in modulating lipid metabolism, we explored the role of HBx in  
121 SREBP-1a activation. Huh-7 cells were transfected with HBx-expressing plasmid and vector control. The  
122 level of SREBP-1 was analyzed by immunoblotting using an anti-SREBP-1 antibody. As shown in the

[Type text]

123 upper panel of Fig. 1A, expression of HBx was associated with increased level of SREBP-1 compared to  
124 control. Because we were interested in SREBP-1a levels especially in the nucleus as the active form,  
125 however the SREBP-1 antibody cannot distinguish SREBP-1a from another isoform SREBP-1c.  
126 Therefore we used a plasmid expressing Flag-tagged SREBP-1a and an anti-Flag antibody to examine  
127 nuclear SREBP-1a levels (lower panel of Fig. 1A). The results showed that the nuclear SREBP-1a protein  
128 level was increased in HBx transfected cells than in vector transfected cells. To determine whether the  
129 increased SREBP-1a correlates with its enhanced activity as a transcription factor, we used an SRE-  
130 luciferase reporter where the luciferase expression is directly controlled by three copies of SRE sequences  
131 (ATCACCCAC, pSRE-Luc) [1]. This is because SREBP-1a activates transcription of its target genes by  
132 binding to the SRE sequence. As shown in Fig. 1B, HBx expression significantly increased SRE-driven  
133 luciferase activity by SREBP-1a compared to control. These results indicate that expression of HBx  
134 increases SREBP-1a level in the nucleus and its transcription factor activity.

135

### 136 *3.2. HBx activates SREBP-1a transcription*

137 SREBPs are often regulated at the transcription level. To determine whether HBx regulates SREBP-1a  
138 transcription, we measured the level of SREBP-1a transcript by real-time PCR after HBx expression in  
139 Huh-7 cells. As shown in Fig. 2A, HBx expression resulted in more than 2-fold increase in SREBP-1a  
140 transcript level in comparison to control. A greater than one genome length HBV plasmid is a widely used  
141 model for HBV. As such, we transfected HBV wild-type genome (pawy1.2) and HBV without HBx  
142 (pawy1.2\*7) [28] into Huh-7 cells and determined SREBP-1a transcript levels. As shown in Fig. 2B,  
143 SREBP-1a transcript level in HBV-transfected cells were significantly higher than those in vector- or  
144 HBV  $\Delta$ HBx-transfected cells. The expression of HBx was confirmed after HBV plasmid transfection,  
145 whereas no HBx could be detected in vector- or HBV $\Delta$ HBx-transfected cells (Fig. 2C). These results  
146 indicate that HBx up-regulates SREBP-1a transcription.

147 To further characterize SREBP-1a transcription up-regulation by HBx, Huh-7 cells were co-  
148 transfected with a luciferase reporter under the control of human SREBP-1a promoter (-1008) [10] and  
[Type text]

149 increasing amounts of HBx-expressing plasmid. The total amounts of plasmid DNA used for transfection  
150 were kept constant by adding appropriate amounts of the vector plasmid. Luciferase assay showed that  
151 HBx significantly activated SREBP-1a promoter activity in a dose-dependent manner in comparison to  
152 vector control (Fig. 2D). Similarly, HBV plasmid transfection resulted in significantly higher luciferase  
153 activity than vector- or HBV $\Delta$ HBx-transfection (Fig. 2E).

154 Next, we wanted to map the regions on the SREBP-1a promoter that were required for its activation  
155 by HBx. We used five truncated SREBP-1a promoters -889, -717, -436, -398, and -360 (Fig. 3A).  
156 Luciferase assay results showed that deletion from -1008 to -436 in the SREBP-1a promoter did not affect  
157 its activation by HBx, whereas the activation was abolished when the -398 and -360 promoters were used.  
158 These results indicate that the sequence between -436 and -398 in the SREBP-1a promoter is required for  
159 its activation by HBx.

160

### 161 *3.3. Effects of C/EBP and E4BP4 on SREBP-1a regulation by HBx*

162 Sequence analysis by the MatINSPECTOR prediction program indicated that the -436 to -398 region  
163 in the SREBP-1a promoter contains binding motifs for transcription factors C/EBP and E4BP4 (Fig. 3B).  
164 To gain the first insights into the role of these two factors in SREBP-1a regulation by HBx, we mutated  
165 the binding sequences for each of the factors in the SREBP-1a promoter (Fig. 3C). These mutant SREBP-  
166 1a promoters were used in co-transfection experiments to test their activity after HBx expression. As  
167 shown in Fig. 3C, HBx failed to activate these mutant SREBP-1a promoters. These results suggested that  
168 the integrity of C/EBP and E4BP4 binding sequences is necessary for SREBP-1a regulation by HBx.  
169 Previous research has established that C/EBP and E4BP4 have divergent effects on transcription, although  
170 both belong to a family of basic leucine zipper (bZIP) proteins [7;34].

171 To determine the effects of these transcription factors in SREBP-1a regulation by HBx, we  
172 studied SREBP-1a promoter activity after ectopic expression of C/EBP $\alpha$  or E4BP4. There are six isoforms  
173 in the C/EBP family and C/EBP $\alpha$  was isolated from the liver [31;34]. Therefore, we used a plasmid  
174 expressing C/EBP $\alpha$ . As shown in Fig. 3D, transfection with increasing amounts of C/EBP $\alpha$  resulted in  
[Type text]

175 dose-dependent SREBP-1a promoter activation in both vector and HBx expressing cells. In contrast,  
176 increasing amounts of E4BP4 resulted in dose-dependent decrease in SREBP-1a promoter activity in both  
177 vector and HBx expressing cells (Figs. 3E). These results indicated that C/EBP $\alpha$  is as an activator,  
178 whereas E4BP4 is a repressor for SREBP-1a promoter regulation by HBx.

179 Opposing effects of C/EBP and E4BP4 on SREBP-1a promoter regulation by HBx raised a  
180 question as to whether the inhibitory effect of E4BP4 can be overcome by C/EBP. To answer this question,  
181 Huh-7 cells were co-transfected with HBx-expressing plasmid and SREBP-1a promoter (-436) - luciferase  
182 reporter, together with E4BP4 alone or with C/EBP $\alpha$ . Corresponding vectors were used as controls. As  
183 shown in Fig. 3F, the inhibition of SREBP-1a promoter activity by E4BP4 was significantly reversed  
184 upon ectopic expression of C/EBP $\alpha$  E4BP4. These results suggest that C/EBP $\alpha$  has a dominantly  
185 activating effect on SREBP-1a promoter activity.

186

### 187 *3.4. Effect of SREBP-1 in HBV enhancer II/core promoter activation by HBx*

188 Our results so far have shown that HBx activates SREBP-1a. Previous studies demonstrated that HBx  
189 increases HBV enhancer II/core promoter activity [5;15]. We therefore interested in determining whether  
190 SREBP-1a is involved in this process. For this purpose, we used a miRNA to knockdown SREBP-1  
191 expression in Huh-7 cells. As shown in Fig. 4A, the levels of both precursor and mature SREBP-1  
192 proteins were reduced by SREBP-1 miRNA in comparison to control miRNA. When Huh-7 cells were  
193 transfected with vector or HBx-expressing plasmids together with pGL4-HBV EN2/CP, modest but  
194 significant 1.5-fold transactivation of enhancer II/core promoter by HBx was observed (Fig. 4B). This  
195 result is consistent with other studies showing activation of enhancer II/core promoter by HBx [5;15].  
196 Upon knockdown SREBP-1, HBx was no longer able to transactivate enhancer II/core promoter (Fig. 4C).  
197 These results demonstrate that SREBP-1 is involved in HBV enhancer II/core promoter transactivation by  
198 HBx.

199

## 200 **4. Discussion**

[Type text]

201 HBx is a multifunctional protein. Here, we demonstrated that HBx activates SREBP-1a, a  
202 transcription factor involved in several (patho)-physiological conditions such as lipogenesis and  
203 carcinogenesis [18;19]. We further demonstrated that SREBP-1 is involved in HBV enhancer II/core  
204 promoter activation by HBx.

205 To become an active transcription factor, SREBP-1a needs to enter the nucleus and therefore nuclear  
206 SREBP-1a level reflects its activity. As such, we first demonstrated that HBx expression is associated  
207 with increased level of SREBP-1a in the nucleus (Fig. 1A). An SRE-driven luciferase reporter assay  
208 confirmed that SREBP-1a in HBx-transfected cells is indeed transcriptionally active (Fig. 1B).

209 The expression of SREBP-1a can be regulated at the transcription level [10]. Our results demonstrated  
210 that HBx can significantly up-regulate the activity of SREBP-1a promoter in a dose-dependent manner  
211 (Fig. 2D). More importantly, we showed that HBx in the context of HBV can also transactivate SREBP-1a  
212 transcription using a plasmid-based HBV model (Figs. 2B and 2E). Mapping the sequences in the SREBP-  
213 1a promoter required for activation by HBx led us to concentrate on two bZIP transcription factors,  
214 namely C/EBP and E4BP4. Mutating the C/EBP binding sequence on the SREBP-1a promoter canceled  
215 SREBP-1a promoter activation by HBx (Fig. 3C). Consistently, ectopic expression of C/EBP $\alpha$   
216 demonstrated that it can further enhance SREBP-1a promoter activation by HBx (Fig. 3D). These results  
217 suggest that C/EBP is required for SREBP-1a activation by HBx.

218 Ectopic expression of E4BP4, on the other hand, has an opposing, inhibiting effect on SREBP-1a  
219 promoter activity (Fig. 3E). This finding is consistent with the established repressor activity of E4BP4 on  
220 transcription [7]. However, when the E4BP4 binding sequence was mutated on the SREBP-1a promoter,  
221 we did not see the expected increase of the promoter activity (Fig. 3C). The underlying reason is not clear.  
222 Several possible mechanisms exist. The binding sequences on gene promoters for bZIP transcription  
223 factors are similar, which may result in DNA binding competition by these factors [7]. In fact, it has been  
224 shown that C/EBP and E4BP4 can compete with each other in DNA binding and regulate transcription in  
225 a competitive manner [22;26]. Therefore, we cannot exclude the possibility that C/EBP can also bind the  
226 E4BP4 sequence on SREBP-1a promoter and positively regulate its activity. As such, elimination of  
[Type text]

227 E4BP4 binding sequence can potentially affect the activities of both E4BP4 and C/EBP. Another  
228 possibility is that mutating the E4BP4 binding motif might somehow negatively affect the binding of  
229 C/EBP to its recognition sequence on the SREBP-1a promoter because they are in a very close proximity.  
230 In addition, b-ZIP factors regulate transcription by forming homo- and/or hetero-dimers [9]. According to  
231 a molecular interaction model, C/EBP and E4BP4 may interact with each other due to the presence of an  
232 asparagine residue in the “a” position of their bZIP domains which would favor heterodimerization [35]. It  
233 is reasonable to assume that elimination of E4BP4 binding sequence on the SREBP-1a promoter may  
234 increase the amount of free E4BP4. Then it is possible that more E4BP4 proteins can interact with C/EBP  
235 and interfere with the activity of C/EBP, resulting in reduced SREBP-1a promoter activation. If this is true,  
236 one would expect that increasing the amount of C/EBP should increase SREBP-1a promoter activity in the  
237 presence of E4BP4. This has been actually observed in our experiments (Fig. 3F). However, the exact  
238 mechanisms warrant further investigation.

239 Recent studies have shown that HBx can activate SREBP-1c, the other isoform of SREBP-1, through  
240 liver X receptor [16;17;24]. Adding to these previous findings, our study has demonstrated that HBx can  
241 also activate SREBP-1a through a different and complex mechanism involving at least two transcription  
242 factors, C/EBP and E4BP4. More importantly, SREBP-1a is a more potent transcription activator for both  
243 fatty acid and cholesterol synthesis pathways [12;29;33]. In contrast, SREBP-1c is less active and only  
244 activates fatty acid synthesis. The functional significance of SREBP-1 activation in HBV biology and  
245 pathogenesis has not been characterized. Towards this goal, we showed that knocking down SREBP-1  
246 abolishes activation of HBV enhancer II/core promoter activation by HBx (Fig. 4). Since the miRNA  
247 sequence we used does not distinguish between SREBP-1a and -1c, further experiments are needed to  
248 determine isoform-specific effects of SREBP-1.

249 In conclusion, our results demonstrated that HBx activates the SREBP-1a activity by a complex  
250 mechanism involving two bZIP transcription factors C/EBP and E4BP4 with the former being the  
251 dominant factor leading to SREBP-1a promoter activation. Furthermore, we showed that SREBP-1 is  
252 involved in HBV enhancer II/core promoter activation by HBx.

[Type text]

253

254 **Acknowledgements**

255 We thank Drs. Betty Slagle, Christopher Richardson, Hitoshi Shimano, Ralf Bartenschlager,  
256 Margarita Melegari, and Ormond A. MacDougald for sharing reagents. This work was supported  
257 by Canadian Institutes of Health Research (CIHR) (ROP-88064 and RSN-109427) and  
258 Saskatchewan Health Research Foundation (SHRF). X.L. is a recipient of a post-doctoral  
259 fellowship from SHRF. This paper is VIDO Manuscript #623.

260

261 **Figure Legends**

262

263 **Figure 1.** Expression of HBx increases the level of nuclear SREBP-1a and its transactivation  
264 activity. **(A).** In the top panel, the levels of HBx, SREBP-1, and  $\beta$ -actin in Huh-7 cells after  
265 transfection with an HBx-expressing plasmid or the vector were analyzed by immunoblotting. In  
266 the bottom panel, levels of SREBP-1a in the nuclear fraction were analyzed by immunoblotting  
267 after co-transfection with plasmids expressing Flag-SREBP-1a and HBx or vector. The blots were  
268 probed with antibodies against Flag-tag or fibrillarlin. **(B).** A luciferase reporter driven by SRE  
269 sequences was co-transfected with a plasmid encoding Flag-SREBP-1a together with HBx-  
270 expressing plasmid or vector control into Huh-7 cells. Luciferase assay was performed using the  
271 cell lysates. Luciferase activity was expressed as fold change relative to vector control. The  
272 statistical difference between samples was demonstrated as \*\* if  $p \leq 0.01$ .

273

274 **Figure 2.** HBx up-regulates SREBP-1a transcription. **(A, B).** Huh-7 cells were transfected with  
275 vector or HBx-expressing plasmids (A), vector, HBV, or HBV  $\Delta$ HBx (B). The levels of SREBP-  
276 1a transcript were analyzed by reverse-transcription real-time PCR. **(C).** The protein levels of  
277 HBx and  $\beta$ -actin in Huh-7 cells after transfection with vector, HBV, or HBV  $\Delta$ HBx were  
278 determined by immunoblotting. **(D, E).** Huh-7 cells were co-transfected with a human SREBP-1a  
[Type text]

279 promoter (-1008/+194)-luciferase reporter plasmid with increasing amounts of HBx-expressing  
280 plasmid (D) or vector, HBV, or HBV  $\Delta$ HBx (E). Luciferase activities were expressed as fold  
281 changes relative to vector control. The statistical differences between samples were demonstrated  
282 as NS for not significant, \* if  $p \leq 0.05$ , or \*\*\* if  $p \leq 0.001$ .

283

284 **Figure 3.** The roles of transcription factors C/EBP and E4BP4 in SREBP-1a promoter regulation  
285 by HBx. (A). Huh-7 cells were transfected with SREBP-1a promoters of different lengths  
286 together with HBx-expressing plasmid or vector control. SREBP-1a promoter activity was  
287 determined by luciferase assay. (B). SREBP-1a promoter sequence -436 to -397. The binding  
288 motifs as well as the mutated sequences for C/EBP and E4BP4 are shown. (C). Sequence  
289 integrity of the SREBP-1a promoter -436 to -398 region is required for its activation by HBx.  
290 Huh-7 cells were co-transfected with wild-type or mutant SREBP-1a promoters with HBx-  
291 expressing plasmid or vector control. SREBP-1a promoter activity was determined by luciferase  
292 assay. (D, E). Huh-7 cells were co-transfected with SREBP-1a-promoter luciferase reporter (-  
293 436/+194), HBx-expressing plasmid or vector control, together with increasing amounts of  
294 C/EBP $\alpha$  (D) or E4BP4 (E). SREBP-1a promoter activity was determined by luciferase assay. (F).  
295 Huh-7 cells were co-transfected with SREBP-1a-promoter luciferase reporter (-436/+194), HBx-  
296 expressing plasmid, together with vector, E4BP4-expressing plasmid, and C/EBP $\alpha$ -expressing  
297 plasmid. SREBP-1a promoter activity was determined by luciferase assay. The statistical  
298 differences between samples were demonstrated as NS for not significant, \* if  $p \leq 0.05$ , \*\* if  $p$   
299  $\leq 0.01$ , or \*\*\* if  $p \leq 0.001$ .

300

301 **Figure 4.** The role of SREBP-1 in HBV enhancer II/core promoter activation by HBx. (A). Huh-7  
302 cells were transfected with control or SREBP-1 miRNAs. The levels of precursor and mature  
303 SREBP-1 were determined by immunoblotting. (B). Huh-7 cells were co-transfected with HBV  
304 enhancer II/core promoter-luciferase reporter pGL4 HBV EN2/CP and vector or HBx-expressing  
[Type text]

305 plasmids. Luciferase activities after HBx expression were expressed as fold changes relative to  
306 vector control. (C). Huh-7 cells were co-transfected with pGL4 HBV EN2/CP, HBx-expressing  
307 plasmid, and control or SREBP-1 miRNA. Luciferase activities after SREBP-1 knockdown were  
308 expressed as fold changes relative to control miRNA-transfection. The statistical differences  
309 between samples were demonstrated as \* if  $p \leq 0.05$ .

310

311

312

313

314

#### Reference List

- 315 [1] M. Amemiya-Kudo, H. Shimano, A.H. Hasty, N. Yahagi, T. Yoshikawa, T.  
316 Matsuzaka, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, J. Osuga, K. Harada, T.  
317 Gotoda, R. Sato, S. Kimura, S. Ishibashi, N. Yamada, Transcriptional activities of  
318 nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and  
319 cholesterogenic genes. *J Lipid Res.* 43 (2002) 1220-1235.
- 320 [2] A.J. Brown, Viral hepatitis and fatty liver disease: how an unwelcome guest makes  
321 pate of the host. *Biochem.J* 416 (2008) e15-e17.
- 322 [3] M.S. Brown, J. Ye, R.B. Rawson, J.L. Goldstein, Regulated intramembrane  
323 proteolysis: a control mechanism conserved from bacteria to humans. *Cell* 100  
324 (2000) 391-398.
- 325 [4] H.C. Cha, N.R. Oak, S. Kang, T.A. Tran, S. Kobayashi, S.H. Chiang, D.G. Tenen,  
326 O.A. MacDougald, Phosphorylation of CCAAT/enhancer-binding protein alpha  
327 regulates GLUT4 expression and glucose transport in adipocytes. *J.Biol.Chem.* 283  
328 (2008) 18002-18011.
- 329 [5] B.H. Choi, G.T. Park, H.M. Rho, Interaction of hepatitis B viral X protein and  
330 CCAAT/ enhancer-binding protein alpha synergistically activates the hepatitis B  
331 viral enhancer II/pregenomic promoter. *J.Biol.Chem.* 274 (1999) 2858-2865.
- 332 [6] A.J. Clippinger, M.J. Bouchard, Hepatitis B virus HBx protein localizes to  
333 mitochondria in primary rat hepatocytes and modulates mitochondrial membrane  
334 potential. *J.Virol.* 82 (2008) 6798-6811.
- 335 [7] I.G. Cowell, E4BP4/NFIL3, a PAR-related bZIP factor with many roles. *Bioessays*  
336 24 (2002) 1023-1029.
- 337 [8] J. Diao, A.A. Khine, F. Sarangi, E. Hsu, C. Iorio, L.A. Tibbles, J.R. Woodgett, J.  
338 Penninger, C.D. Richardson, X protein of hepatitis B virus inhibits Fas-mediated

[Type text]


- 339 apoptosis and is associated with up-regulation of the SAPK/JNK pathway. *J Biol*  
340 *Chem.* 276 (2001) 8328-8340.
- 341 [9] J. Fassler, D. Landsman, A. Acharya, J.R. Moll, M. Bonovich, C. Vinson, B-ZIP  
342 proteins encoded by the *Drosophila* genome: evaluation of potential dimerization  
343 partners. *Genome Res.* 12 (2002) 1190-1200.
- 344 [10] A. Fernandez-Alvarez, G. Tur, G. Lopez-Rodas, M. Casado, Reciprocal regulation  
345 of the human sterol regulatory element binding protein (SREBP)-1a promoter by  
346 Sp1 and EGR-1 transcription factors. *FEBS Lett.* 582 (2008) 177-184.
- 347 [11] J.D. Horton, J.L. Goldstein, M.S. Brown, SREBPs: activators of the complete  
348 program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest* 109 (2002)  
349 1125-1131.
- 350 [12] S.S. Im, L.E. Hammond, L. Yousef, C. Nugas-Selby, D.J. Shin, Y.K. Seo, L.G.  
351 Fong, S.G. Young, T.F. Osborne, Sterol regulatory element binding protein 1a  
352 regulates hepatic fatty acid partitioning by activating acetyl coenzyme A  
353 carboxylase 2. *Mol.Cell Biol.* 29 (2009) 4864-4872.
- 354 [13] C. Jackel-Cram, L.A. Babiuk, Q. Liu, Up-regulation of fatty acid synthase promoter  
355 by hepatitis C virus core protein: Genotype-3a core has a stronger effect than  
356 genotype-1b core. *J Hepatol.* 46 (2007) 999-1008.
- 357 [14] C. Jackel-Cram, L. Qiao, Z. Xiang, R. Brownlie, Y. Zhou, L. Babiuk, Q. Liu,  
358 Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-  
359 binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway.  
360 *J.Gen.Virol.* 91 (2010) 1388-1395.
- 361 [15] V.V. Keasler, A.J. Hodgson, C.R. Madden, B.L. Slagle, Enhancement of hepatitis B  
362 virus replication by the regulatory X protein in vitro and in vivo. *J.Virol.* 81 (2007)  
363 2656-2662.
- 364 [16] K. Kim, K.H. Kim, H.H. Kim, J. Cheong, Hepatitis B virus X protein induces  
365 lipogenic transcription factor SREBP1 and fatty acid synthase through the  
366 activation of nuclear receptor LXRalpha. *Biochem.J* 416 (2008) 219-230.
- 367 [17] K.H. Kim, H.J. Shin, K. Kim, H.M. Choi, S.H. Rhee, H.B. Moon, H.H. Kim, U.S.  
368 Yang, D.Y. Yu, J. Cheong, Hepatitis B Virus X Protein Induces Hepatic Steatosis  
369 Via Transcriptional Activation of SREBP1 and PPARgamma. *Gastroenterology* 132  
370 (2007) 1955-1967.
- 371 [18] J.R. Krycer, L.J. Sharpe, W. Luu, A.J. Brown, The Akt-SREBP nexus: cell  
372 signaling meets lipid metabolism. *Trends Endocrinol.Metab* 21 (2010) 268-276.
- 373 [19] C.A. Lewis, B. Griffiths, C.R. Santos, M. Pende, A. Schulze, Regulation of the  
374 SREBP transcription factors by mTORC1. *Biochem.Soc.Trans.* 39 (2011) 495-499.


[Type text]


- 375 [20] V. Lohmann, F. Korner, J. Koch, U. Herian, L. Theilmann, R. Bartenschlager,  
376 Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science*  
377 285 (1999) 110-113.
- 378 [21] J. Lucifora, S. Arzberger, D. Durantel, L. Belloni, M. Strubin, M. Levrero, F.  
379 Zoulim, O. Hantz, U. Protzer, Hepatitis B virus X protein is essential to initiate and  
380 maintain virus replication after infection. *J.Hepatol.* 55 (2011) 996-1003.
- 381 [22] H.D. MacGillavry, J. Cornelis, L.R. van der Kallen, M.M. Sassen, J. Verhaagen,  
382 A.B. Smit, R.E. van Kesteren, Genome-wide gene expression and promoter binding  
383 analysis identifies NFIL3 as a repressor of C/EBP target genes in neuronal  
384 outgrowth. *Mol.Cell Neurosci.* 46 (2011) 460-468.
- 385 [23] N. Moolla, M. Kew, P. Arbuthnot, Regulatory elements of hepatitis B virus  
386 transcription. *J.Viral Hepat.* 9 (2002) 323-331.
- 387 [24] T.Y. Na, Y.K. Shin, K.J. Roh, S.A. Kang, I. Hong, S.J. Oh, J.K. Seong, C.K. Park,  
388 Y.L. Choi, M.O. Lee, Liver X receptor mediates hepatitis B virus X protein-induced  
389 lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. *Hepatology* 49  
390 (2009) 1122-1131.
- 391 [25] S.A. Ng, C. Lee, Hepatitis B virus X gene and hepatocarcinogenesis.  
392 *J.Gastroenterol.* 46 (2011) 974-990.
- 393 [26] I.C. Ozkurt, S. Tetradis, Parathyroid hormone-induced E4BP4/NFIL3 down-  
394 regulates transcription in osteoblasts. *J.Biol.Chem.* 278 (2003) 26803-26809.
- 395 [27] C. Ramiere, C. Scholtes, O. Diaz, V. Icard, L. Perrin-Cocon, M.A. Trabaud, V.  
396 Lotteau, P. Andre, Transactivation of the hepatitis B virus core promoter by the  
397 nuclear receptor FXRalpha. *J.Virol.* 82 (2008) 10832-10840.
- 398 [28] P.P. Scaglioni, M. Melegari, J.R. Wands, Posttranscriptional regulation of hepatitis  
399 B virus replication by the precore protein. *J.Virol.* 71 (1997) 345-353.
- 400 [29] H. Shimano, Sterol regulatory element-binding protein family as global regulators  
401 of lipid synthetic genes in energy metabolism. *Vitam.Horm.* 65 (2002) 167-194.
- 402 [30] H. Shimano, J.D. Horton, I. Shimomura, R.E. Hammer, M.S. Brown, J.L. Goldstein,  
403 Isoform 1c of sterol regulatory element binding protein is less active than isoform  
404 1a in livers of transgenic mice and in cultured cells. *J.Clin.Invest* 99 (1997) 846-854.
- 405 [31] M. Takiguchi, The C/EBP family of transcription factors in the liver and other  
406 organs. *Int.J.Exp.Pathol.* 79 (1998) 369-391.
- 407 [32] H. Tang, N. Oishi, S. Kaneko, S. Murakami, Molecular functions and biological  
408 roles of hepatitis B virus x protein. *Cancer Sci.* 97 (2006) 977-983.


- 409 [33] J.I. Toth, S. Datta, J.N. Athanikar, L.P. Freedman, T.F. Osborne, Selective  
410 coactivator interactions in gene activation by SREBP-1a and -1c. *Mol.Cell Biol.* 24  
411 (2004) 8288-8300.
- 412 [34] J. Tsukada, Y. Yoshida, Y. Kominato, P.E. Auron, The CCAAT/enhancer (C/EBP)  
413 family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-  
414 regulated system for gene regulation. *Cytokine* 54 (2011) 6-19.
- 415 [35] C. Vinson, A. Acharya, E.J. Taparowsky, Deciphering B-ZIP transcription factor  
416 interactions in vitro and in vivo. *Biochim.Biophys.Acta* 1759 (2006) 4-12.
- 417 [36] Z. Xiang, L. Qiao, Y. Zhou, L.A. Babiuk, Q. Liu, Hepatitis C virus nonstructural  
418 protein-5A activates sterol regulatory element-binding protein-1c through  
419 transcription factor Sp1. *Biochem.Biophys.Res.Commun.* 402 (2010) 549-553.  
420  
421

Qiao, et al., Figure 1









1. HBx increases mature SREBP-1a protein level
2. HBx activates SREBP-1a transcription
3. C/EBP and E4BP4 are involved in SREBP-1a promoter regulation by HBx
4. SREBP-1 is involved in HBV enhancer II/core promoter activation by HBx

ACCEPTED MANUSCRIPT